20040266002 | Use of abscisic acid in somatic embryogenesis of pine trees | December, 2004 | Carpenter |
20020106658 | Blocking chemistries for nylon membrane | August, 2002 | Wells et al. |
20060147897 | Characterization of arteriosclerosis by optical imaging | July, 2006 | Grinvald et al. |
20100040660 | DEVELOPMENT OF A TISSUE - ENGINEERED SCAFFOLD FOR NERVE REGENERATION USING A BIOCOMPATIBLE AND INJECTABLE HYDROGEL | February, 2010 | Kim et al. |
20020164770 | DNA transfection system for the generation of infectious influenza virus | November, 2002 | Hoffmann |
20030170624 | Single nucleotide polymorphisms and their use in genetic analysis | September, 2003 | Goelet et al. |
20050129615 | Non-invasive system for detecting skin cancer | June, 2005 | Rozga et al. |
20090075933 | CYTOCOMPATIBLE ALGINATE GELS | March, 2009 | Basu et al. |
20080318258 | Method for Measuring Cholesterol in Remnant-Like Lipoprotein | December, 2008 | Ogihara et al. |
20050095259 | Manufacturing method for entomopathogenic fungi | May, 2005 | Liu |
20060159673 | Methods of screening light chain of antibody | July, 2006 | Kojima |
[0002] As defined herein, the group
[0003]
[0004] Carbon catabolite repression (CCR) is a regulatory mechanism allowing bacteria to choose between different carbon sources according to their metabolic value and to switch from a carbon source to another depending on their availability in the growth medium. A well-known manifestation of catabolic repression is the diauxic growth that occurs when bacteria are grown in presence of both glucose and lactose. Diauxic growth curves show two distinct phases of exponential growth, separated by a lag phase. During the first phase of growth, glucose represses the synthesis of the enzymes necessary for lactose utilisation, and is therefore the only source of energy of the bacteria. When all the glucose is exhausted occurs the lag phase, during which the enzymes for lactose utilisation are synthesised, allowing lactose to be used as a source of energy during the second phase of growth.
[0005] A main target of catabolite repression is the transport of sugars into the bacterial cell. In
[0006] The PTS of gram-positive bacteria has been studied mainly in
[0007] It has been shown that components of the PTS, and more specifically the enzyme HPr, are also involved in other regulatory pathways.
[0008] For instance, P-His-HPr can transfer its phosphoryl group also to non-PTS proteins, such as glycerol kinase [CHARRIER et al., J. Biol. Chem., 272, 14166-14174, (1997)] or antiterminators and transcriptional activators possessing the PTS regulation domain (PRD) which contains several phosphorylation sites recognised by P-His-HPr [TORTOSA et al., J. Biol. Chem., 272, 17230-17237, (1997); STÜLKE et al., Mol. Microbiol., 28, 865-874, (1998); LINDNER et al., Mol. Microbiol., 31, 995-1006, (1999)]. In all cases, P-His-HPr-dependent phosphorylation leads to the activation of the function of the non-PTS proteins and this phosphorylation has been shown to serve as a secondary carbon catabolite repression mechanism in Gram-positive bacteria [DEUTSCHER et al., J. Bacteriol., 175, 3730-3733, (1993); KRÜGER et al., J. Bacteriol., 178, 2637-2644, (1996); MARTIN-VERSTRAETE et al., Mol. Microbiol., 28, 293-303, (1998)]. In Lactobacillus casei, the antiterminator LacT, which regulates the expression of the lac operon, contains two PRD and seems to be controlled by this mechanism.
[0009] In Gram-positive bacteria, HPr may also be phosphorylated by the bifunctional HPr kinase/phosphatase HprK [GALINIER et al., Proc. Natl. Acad. Sci. USA, 95, 1823-1828, (1998); REIZER et al., Mol. Microbiol., 27, 1157-1169, (1998); BROCHU and VADEBONCOEUR, J. Bacteriol., 181, 709-717, (1999); KRAVANJA et al., Mol. Microbiol., 31, 59-66, (1999)1. In
[0010] Genes encoding components of CCR system, and more specifically genes related to the PTS, such as ptsI and ptsH encoding respectively the enzymes EI and HPr of the PTS system, hprK encoding the HPr kinase/phosphatase, and ccpA have been characterised in some species of Gram-positive bacteria.
[0011] In
[0012] The inventors have recently identified, cloned and sequenced the ptsI, ptsH and hprK genes of
[0013] The nucleotidic sequence of the ptsHI operon, and the peptidic sequences of HPr and EI of
[0014] The inventors have now studied the effect of mutations in ptsI, ptsH and hprK, as well as the effect of mutations in ccpA on growth and metabolic properties of
[0015] An object of the present invention is the use of a mutant of
[0016] Preferably, said mutant is selected from the group consisting of:
[0017] a) mutants having at least a mutation impairing the regulation of CCR through P-His-HPr;
[0018] b) mutants having at least a mutation impairing the regulation of CCR through P-Ser-HPr.
[0019] Mutations of sub-group a) include in particular:
[0020] mutations in genes encoding the components of the PTS, for instance: any mutation in the ptsH gene impairing the ability of HPr to be phosphorylated at His-15, or to phosphorylate EIIA; any mutation in the ptsI gene impairing the ability of EI to phosphorylate HPr at His-15; any mutation in a gene encoding an enzyme EIIA, EIIB, or EIIC impairing the transfer of a phosphoryl group to a carbohydrate;
[0021] mutations in genes encoding antiterminators or transcriptional activators having the PTS regulation domain, for instance any mutation impairing the phosphorylation of any of these antiterminators or transcriptional activators by P-His-HPr and/or by P-EIIB or mimicking the phosphorylated form of the antiterminator (for example phosphorylatable histidyl residues mutated to Asp or Glu);
[0022] mutations destroying terminators located in front of genes regulated by antiterminators which are phosphorylated and controlled by P-His-HPr and/or by P-EIIB.
[0023] Mutations of sub-group b) include in particular: any mutation in the ptsH gene impairing the ability of HPr to be phosphorylated at Ser-46; any mutation in the hprK gene impairing the ability of HprK to phosphorylate HPr at Ser-46; any mutation in the ptsH gene or in the ccpA gene impairing the formation of a complex between CcpA and P-Ser-HPr or the binding of said complex to cre elements; any mutation in said cre elements impairing their ability to bind said CcpA/P-Ser-HPr complex.
[0024] Non-limitative examples of mutants of
[0025] mutants having at least a mutation in the ptsI gene resulting in the lack of expression of enzyme EI, or in the expression of an enzyme EI devoid of at least an active domain of wild-type EI. For instance, a mutant of the invention may be obtained by introduction of a frameshift mutation at location 870 of the sequence SEQ ID NO:1. The insertion of four nucleotides (sequence AATT) at this location results in a stop codon four codons after the site of insertion. This results in the expression of a truncated EI protein devoid of at least aminoacids 110 to 574 of wild-type EI, with the addition of four new codons before the first translational stop codon.
[0026] mutants having at least a mutation in the hprK gene resulting in the lack of expression of HprK or in the expression of a HprK devoid of at least an active domain of wild-type HprK. For instance, a mutant of the invention may be devoid of at least aminoacids 208 to 319 of wild-type HprK.
[0027] mutants having at least a mutation in the ccpA gene resulting in the lack of expression of CcpA or in the expression of a CcpA devoid of at least an active domain of wild-type CcpA. For instance, a mutant of the invention may be obtained by introduction of a frameshift mutation at location 710 of the sequence U28137 of GENBANK. The insertion of four nucleotides (sequence AATT) at this location results in a stop codon five codons after the site of insertion, and in the expression of a CcpA devoid of at least aminoacids 134 to 333 of wild-type CcpA. - mutants in the ptsH gene having at least a mutation resulting in the lack of expression of HPr or in the expression of a HPr having at least one amino-acid substitution at position 15 and/or at position 46 and/or at position 47 of wild-type HPr, and/or at least a mutation resulting in the expression of a HPr deleted of at least one of amino-acids 15, 46, and/or 47 of wild-type HPr.
[0028] The invention also provides:
[0029] mutants of
[0030] food-grade mutants of
[0031] “Food-grade mutants” are herein defined as mutant bacteria acceptable for use in preparation of food. To be food-grade, the mutants must not comprise sequences derived from microorganisms other than the ones used in food industry. Preferably, they must not comprise sequences derived from microorganisms other than those belonging to the species from which the mutant derives. Also they must not comprise potentially harmful DNA sequences such as antibiotic resistance genes.
[0032]
[0033] Mutants of the invention may be obtained by the conventional molecular biology methods. From the sequences of
[0034] Said mutations may for instance be obtained by the deletion of said regulatory DNA sequence or of the said insertion, deletion, and/or substitution of one nucleotide or of several nucleotides, adjacent or not.
[0035] Such mutations include in particular any mutation resulting in the production of a protein having at least one deletion, insertion, or non-conservative substitutions of one or several amino acid residues in a domain essential for the biological activity of said protein.
[0036] The mutant gene thus obtained is then cloned into a vector, preferably an expression vector, and used to transform
[0037] By way of example, one can use an extrachromosomal vector able to replicate in
[0038] Integration of the mutant gene into the bacterial chromosome occurs by recombination of the vector genetic material at a homologous site (generally the wild-type allele of the mutant gene) on the bacterial chromosome. Integration may result from a single or double recombination event. Single recombination events result in integration of the entire vector. Double recombination events lead to the excision of the exogenous vector sequences.
[0039] By way of example, a method for integration of a mutant lacT, lacE, or lacF gene in the chromosome of
[0040] Such a method can be used, for instance, for obtaining food-grade mutants wherein the function of EI, HPr, HprK, or CcpA is completely or partially impaired. This method comprises:
[0041] transforming
[0042] culturing the bacteria under selective conditions for the marker gene (for instance, if the marker gene is an antibiotic resistance gene, in presence of the corresponding antibiotic) and recovering the bacteria able to grow in these conditions, i.e. having integrated the vector into their chromosome by a single recombination event;
[0043] culturing said bacteria under non-selective conditions for the marker gene in order to obtain bacteria having undergone a double recombination event leading to the excision of the vector sequences.
[0044] This double recombination event produces bacteria having a wild-type phenotype and bacteria having the desired mutation. The latter can then be screened on the basis of their phenotypic properties, and/or by PCR amplification of the chromosomic region wherein the mutation was targeted and analysis of the amplification products (for instance comparison of the restriction profiles). The presence of the desired mutation can further be confirmed by DNA sequencing.
[0045] A preferred method for obtaining food-grade mutants wherein the catalytic function of HPr is only slightly impaired comprises:
[0046] transforming a mutant strain of
[0047] culturing the transformed bacteria on lactose under selective conditions for the marker gene, and recovering the bacteria having integrated the vector into their chromosome by a single recombination event;
[0048] culturing the selected bacteria on lactose and under non-selective conditions for the marker gene in order to obtain bacteria having undergone a double recombination event leading to the excision of the vector sequences.
[0049] Clones containing an intact ptsI gene and a mutated ptsH gene can be selected on the basis of their slightly reduced growth on lactose. The presence of the mutation can be confirmed by DNA sequencing.
[0050] Mutant strains of the invention can also be obtained from wild-type strains of
[0051] For instances, reporter gene fusions to catabolite repressed or activated genes could be used to identify ccpA, ptsH or hprK mutants defective in carbon catabolite repression or carbon catabolite activation.
[0052] Mutant strains of the invention may also be selected on the basis of their metabolic properties. For instance: mutants in the ptsI or ptsH gene may be selected on the basis of their resistance to 2-deoxy glucose. Mutants in the ptsI gene or mutants in the ptsH gene having an inactive EI or HPr, respectively, may also be selected on the basis of their ability to grow on non-PTS sugar but not on PTS sugars.
[0053] The invention also provides a process for preparing a food product or food additive wherein said process comprises fermenting a food substrate with a mutant strain of
[0054] Preferably said food product is a dairy product.
[0055] According to a preferred embodiment, the process of the invention comprises preparing a food product enriched with aroma compounds (such as acetate, acetoin, diacetyl, hydroxy-3-pentanone, propionate) by fermenting a food substrate with a strain of
[0056] According to another preferred embodiment, the process of the invention comprises preparing a food product having an improved texture and flavor by fermenting a food substrate with a strain of
[0057] The invention also provides fermented food products obtainable by the process of the invention, and, in particular fermented food products comprising at least a mutant strain of
[0058] The present invention will be further illustrated by the additional description which follows, which refers to examples of construction and use of mutant strains of
[0059] Strains, Plasmids and Culture Conditions
[0060] The TABLE 1a STRAIN (L. casei) GENOTYPE ORIGIN BL23 wild-type Bruce Chassy BL30 man (VEYRAT et al,, 1994) BL71 ccpA (MONEDERO et al., 1997) BL72 man ccpA (GOSALBES et al., 1997) BL121 ptsH1 (S46AHPr) This work BL122 ptsH2 (S46THPr) This work BL123 ptsH3 (I47THPr) This work BL124 ptsI: pVME800 This work BL126 ptsI1 (frameshift introduced into This work the first EcoRI site of ptsI)
[0061]
TABLE 1b ORIGIN PLASMID PHARMACIA- pUC18 PROPERTIES BIOTECH pRV300 pBluescript SK- with the pAMβ1 (LELOUP et EmR gene al., 1997) pUCR-HI pUC18 with 1.6 kb PCR fragment This work with part of ptsH and ptsI pVME800 pRV300 with a 865 bp EcoRI This work internal ptsI fragment pVMS1 pRV300 with 9 kb fragment This work downstream from ptsI pVMH1 pRV300 with part of ptsI, complete This work ptsH and 105 bp upstream from ptsH pVMH2 pVMH1 derivative This work (codon 46 of ptsH is GCT for Ala) pVMH3 pVMH1 derivative This work (codon 46 of ptsH is ACT for Thr) pVMH4 pVMH1 derivative This work (codon 46 of ptsH is GAT for Asp) pVMH5 pVMH1 derivative This work (codon 47 of ptsH is ACC for Thr) pVMR10 pVMH1 derivative with a frameshift in This work the first EcoRI site of ptsI.
[0062]
[0063] For diauxic growth experiments,
[0064] Transformed bacteria were plated on the respective solid media containing 1.5% agar. The concentrations of antibiotics used for the selection of
[0065] The sugar utilization pattern of certain strains was determined with the API50-CH galeries (BIOMERIEUX, Marcy l'Etoile, France).
[0066] Purification of HPr
[0067] Cells from an over-night culture (1 l of MRS medium) were centrifuged and washed twice with 20 mM Tris-HCl, pH 7.4. The cells were resuspended in 20 mM ammonium bicarbonate buffer, pH 8 (2 ml per gram of cell pellet), sonicated (BRANSON SONIFIER 250) and then centrifuged to remove the cell debris. As HPr resists to heat treatment, the supernatant was kept at 70° C. for 5 min to precipitate most of the other proteins. An additionnal centrifugation step was performed to remove the heat-denatured proteins. The supernatant was loaded on a Sephadex G-75 column (42 cm×1.6 cm) equilibrated with 20 mM ammonium bicarbonate, pH 8, which was eluted with the same buffer, and fractions of 1.5 ml were collected. To test for the presence of HPr in these fractions, a mutant complementation assay with the
[0068] Half of the partially purified HPr was separated by reverse phase chromatography on a VYDAC C-18 HPLC column (300 Å, 250 mm×4.6 mm; TOUZART ET MATIGNON, France). Solvent A was an aqueous solution of 0.1% (v/v) of trifluoroacetic acid and solvent B contained 80% acetonitrile and 0.04% trifluoroacetic acid. Proteins were eluted with a linear gradient from 5 to 100% of solvent B in 60 min at a flow rate of 500 μl/min. Fractions with a volume of about 500 μl were collected manually. The presence of HPr in the fractions was tested by a PEP-dependent phosphorylation assay containing 10 mM MgCl
[0069] Cloning of PCR-amplified
[0070] To amplify
[0071] where R stands for A or G, Y for C or T, S for C or G and N for any nucleotide. Shown underlined in parentheses are the N-terminal amino acid sequence of HPr and the conserved enzyme I sequences which served to design the primers.
[0072] PCR amplification of the two fragments comprising part of the ptsHI operon, was performed with a PROGENE thermocycler (REAL, S. L., Valencia, Spain) programmed for 30 cycles including the following three steps: 30 sec at 95° C., 30 sec at 50° C. and 1 min at 72° C., followed by a final extension cycle at 72° C. for 5 min.
[0073] Two combinations of primers (PTS-H2/PTS-I3 and PTS-H2/PTS-I4) gave PCR-amplified fragments of 1.6 kb and 0.3 kb, respectively. Sequencing of the PCR products revealed that the deduced amino acid sequences exhibited strong similarity to the sequences of known enzyme I and HPr. As expected, both DNA fragments began with the 5′ end of ptsH and extended to the region in ptsI encoding the conserved sequence chosen as basis for the second primer. The larger of the two fragments obtained with primer PTS-I3 was cloned into pUC18, providing plasmid pUCR-H1. Cloning of PCR fragments was achieved with the SURECLONE Ligation Kit (PHARMACIA BIOTECH, Ltd., Uppsala, Sweden).
[0074] A 865 bp EcoRI fragment which contained an internal part of the ptsI gene was obtained from plasmid pUCR-H1 and subcloned into the suicide vector pRV300 [LELOUP et al., Appl. Environm. Microbiol., 63, 2117-2123, (1997)], providing plasmid pVME800.
[0075] This plasmid was used to transform the
[0076] Restriction analysis of the ptsHI region was carried out by southern hybridisation using DNA isolated from one integrant (BL124) with the aim to identify restriction enzymes allowing cloning of the ptsH and ptsI genes together with their flanking regions.
[0077] Cloning of the regions flanking the insertion site of plasmid pRV300 was performed as follows: DNA (10 μg) from
[0078] Digestion of BL124 DNA with SacI and religation of the obtained DNA fragments allowed to isolate plasmid pVMS1 carrying an about 9 kb insert. Partial sequencing of this insert revealed that it contained the 3′ part of ptsI and its downstream region. The same experiment carried out with HindIII allowed to isolate plasmid pVMH1 carrying a 2.4 kb insert comprising the complete ptsH gene together with part of its promoter region and the 5′ part of ptsI.
[0079] The sequence containing the complete ptsH promoter and 560 bp of the upstream region was subsequently obtained by reverse PCR. For this purpose, DNA isolated from the
[0080] In total, a continuous stretch of 4150 bp has been sequenced. It contained the complete ptsH and ptsI genes and an open reading frame (ORF) located downstream of ptsI. The stop codon of ptsH was found to overlap with the initiation codon of ptsI by 1 bp, suggesting that these two genes are organised in an operon. Whereas the encoded
[0081]
[0082] Transcriptional Analysis of the
[0083] To determine the size of the ptsHI transcripts and to test the effect of a man (prevents the uptake of glucose via the PTS) and a ccpA mutation on ptsHI expression, Northern blots were performed with RNA isolated not only from the
[0084]
[0085] Hybridisation experiments were carried out with either ptsH- or ptsI-specific probes. With both probes, a mRNA band of about 2.1 kb could be detected, which is in good agreement with the size expected for the combined ptsH and ptsI genes, confirming that these two genes are organised in an operon and that transcription stops at the stem loop structure located downstream of ptsI.
[0086] Densitometric measurement of the hybridising bands in the RNA isolated from cells of the different mutants grown in glucose-, lactose-, or ribose-containing medium showed that expression of the ptsHI operon was moderately induced by glucose in the wild type and ccpA mutant, while this effect was less pronounced in the strains carrying the man mutation.
[0087] I—Construction and Characterisation of ptsI Mutants Mutant BL124
[0088] This mutant results from transformation of
[0089] In contrast to the wild-type strain, this mutant can no longer produce acid from fructose, mannose, mannitol, sorbose, sorbitol, amygdaline, arbutine, salicine, cellobiose, lactose, tagatose, trehalose and turanose. However, it can still metabolise ribose, galactose, glucose, N-acetylglucosamine, aesculine, maltose and gluconate, suggesting that in
[0090] Mutant BL126
[0091] Plasmid pVMH1 was partially digested with EcoRI and made blunt end (filled in with the Klenow fragment) before it was religated and used to transform
[0092] From this strain, a ptsI mutant (ptsI1, BL126) could be obtained by a second recombination. BL126 was erythromycin-sensitive and exhibited a fermentation pattern identical to that found for the ptsI: :pVME800 mutant BL124. Interestingly, no ptsHI mRNA could be detected in BL126 by Northern blot analysis.
[0093] II—Construction of ptsH Mutants Altered at Ser-46 or Ile-47
[0094] PCR-based site directed mutagenesis was carried out with the
[0095] Site-directed mutagenesis was performed in order to replace the codon for Ser-46 of
[0096] For this purpose, PCR amplification was carried out using as template the plasmid pVMH1 containing the
[0097] 5′ptsHS46A (5′-AAG AGC GTT AAC TTG AAG GCT ATC ATG GGC G-3′);
[0098] 5′ptsHS46T (5′-AAG AGC GTT AAC TIG AAG ACT AIC ATG GGC G-3′);
[0099] 5′ptsHS46D (5′-AAG AGC GTT AAC TIG AAQ GAT ATC ATG GGC G-3′);
[0100] 5′ptsHI47T (5′-AAG AGC GTT AAC TIG AAG TCT ACC ATG GGC G-3′).
[0101] In these oligonucleotides, the codons for Ser-46 or Ile-47 were replaced by the indicated codon (underlined).
[0102] The resulting 1.4 kb PCR fragments containing the ptsH alleles (from codon 40) and the 5′ part of ptsI were digested with HpaI (the HpaI site present in ptsH before codon 46 is indicated in italics in the above primers) and SacI and used to replace the wild-type 1.4 kb HpaI/SacI fragment in pVMH1.
[0103] In order to confirm the presence of the mutations, the sequence of the ptsH alleles was determined in the four constructed plasmids. To eliminate mutations possibly introduced in the ptsI gene by the PCR amplification, the 1.35 kb BalI/SacI fragment from pVMH1 was used to replace the corresponding fragment in each of the four plasmids containing the various ptsH alleles. A unique BalI site is present 2i bp behind codon 46 of
[0104] The four resulting plasmids carrying the various ptsH alleles were named pVMH2, pVMH3, pVMH4 and pVMH5, respectively (Table 1), and were used to transform the
[0105]
[0106] Integrants obtained by the first (1) and second (2) type of recombination exhibited a lac
[0107] The three different DNA arrangements presented on
[0108] Transformation or the
[0109] Type 3 integrants obtained with each of the three pVMH plasmids were grown for 200 generations without selective pressure to allow the second recombination leading to the excision of the PVMH plasmids. Erythromycin-sensitive clones able to ferment lactose were therefore isolated.
[0110] Two types of erythromycin-sensitive lactose-fermenting recombinants were obtained which exhibited slightly different growth characteristics. Using appropriate primers, the ptsH alleles of two clones of the slower and faster growing recombinants were amplified by PCR and sequenced. For each ptsH allele, the two faster growing clones contained the wild-type ptsH, whereas the slightly slower growing strains carried either the Ser-46-Ala (ptsH1, BL121), the Ser-46-Thr (ptsH2, BL122) or the Ile-47-Thr ptsH mutation (ptsH3, BL123).
[0111] No strain synthesising Ser-46-Asp mutant HPr could be obtained with this method, although PCR amplification followed by DNA sequencing was carried out with fifteen erythromycin-sensitive clones constructed with plasmid pVMH4.
[0112] The ptsH Mutations Affect CCR and Diauxic Growth
[0113] In order to test the effect of the different amino acid substitutions in HPr on diauxie, the growth behaviour of the mutants on basal MRS broth supplemented with 0.1% glucose and 0.2% lactose was compared to that of the wild-type and a ccpA mutant.
[0114]
[0115] As previously demonstrated [VEYRAT et al., Microbiology, 140, 1141-1149, (1994); GOSALBES et al., FEMS Microbiol. Lett., 148, 83-89, (1997); GOSALBES et al., J. Bacteriol., 181, 3928-3934, (1999)], the
[0116] A similar gradation was found when the relief from glucose-mediated repression of N-acetyglucosaminidase activity was investigated.
[0117] For the N-acetylglucosaminidase assays, permeabilized
[0118]
[0119] Whereas high activity of this enzyme could be measured in ribose-grown wild-type cells, glucose was found to inhibit its activity about 10-fold. Similar as in the ccpA mutant, the repressive effect of glucose on N-acetylglucosaminidase had completely disappeared in the ptsHS46A mutant. Inhibition of N-acetylglucosaminidase activity by the presence of glucose in the growth medium was also clearly diminished in the two other ptsH mutants (about 2-fold inhibition in the ptsHI47T mutant and 2.5-fold inhibition in the ptsHS46T mutant), confirming the importance of Ser-46 phosphorylation of HPr and of the amino acids in the vicinity of Ser-46 for CCR in
[0120] Therefore, these two tests indicated that there was a remarkable and progressive loss of catabolite repression in the different mutants:wild-type<ptsH2<ptsH3<ptsH1<ccpA.
[0121] The ptsH Mutations Affect Inducer Exclusion in
[0122] When
[0123] In order to distinguish whether this effect was mediated via interaction of the CcpA/P-Ser-HPr complex with cre sequences or via interaction of P-Ser-HPr with a sugar permease according to the proposed mechanism of inducer exclusion [YE et al., Proc. Natl. Acad. Sci. USA, 91, 3102-3106, (1994); YE et al., J. Bacteriol., 176, 3484-3492, (1994); YE and SAIER, Proc. Natl. Acad. Sci. USA, 92, 417-421, (1995); YE and SAIER, J. Bacteriol., 177, 1900-1902, (1995)], sugar transport experiments were performed.
[0124] Cells were grown to mid-exponential phase in MRS fermentation broth containing 0.5% of the indicated sugars. Subsequently, glucose was added to a final concentration of 0.5% and cells were grown for a further 30 min to allow the synthesis of the glucose-specific PTS transport proteins. Cells were washed twice with 50 mM sodium phosphate buffer, pH 7, containing 10 mM MgCl2 and resuspended in 50 mM Tris-maleate buffer, pH 7.2, containing 5 mM MgCl
[0125]
[0126] The uptake of ribose by ribose-grown
[0127] In contrast to the stimulatory effect exerted by glucose on ribose uptake, maltose transport was found to be instantaneously arrested when glucose or 2-deoxyglucose was added to
[0128] The measure of glucose uptake in the ptsI mutant BL126 shows that glucose is transported 10-times slower than the wild-type strain (data not shown). A slower glucose uptake and metabolism is most likely responsible for the failure of glucose to elicit inducer exclusion in the ptsI mutant strain. By contrast, in a ccpA mutant strain, glucose exerts an inhibitory effect on maltose uptake identical to that observed with the wild-type strain. This result clearly establishes that CcpA is not involved in glucose-triggered maltose exclusion.
[0129] To make sure that growing the cells for 30 min in glucose-containing medium had no drastic effect on expression of the maltose genes, inducer exclusion experiments were carried out with cells which had not been exposed to glucose. Under these conditions, addition of glucose to maltose transporting cells exerts a strong inhibitory effect on maltose uptake in the wild-type and ccpA mutant strains, although maltose continues to be slowly taken up by these cells after the addition of glucose. By contrast, the presence of glucose completely arrests maltose uptake by cells which have been grown on glucose for 30 min. However, with the ptsH1, ptsH2 and ptsH3 mutants grown only on maltose, glucose exerts no inhibitory effect at all on maltose uptake, clearly establishing that the failure of glucose to inhibit maltose transport in the ptsH mutant strains is not related to pregrowing the cells in glucose-containing medium.
[0130] The observed inhibition of maltose transport could have been due to elevated secretion of maltose fermentation products when glucose was added to wild-type cells. In the ptsH mutants, this glucose effect might have been less pronounced. To exclude this possibility, we also measured sugar consumption by resting cells which had been grown on maltose and for the last 30 min before harvesting the cells on maltose and glucose. In order to follow the sugar consumption by the
[0131]
[0132] The results presented in
[0133] Strains, Plasmids and Culture Conditions
[0134] The
[0135]
[0136] The plasmids used in this study were pBC KS
[0137] Cloning of hprK Gene
[0138] DNA Amplification by PCR
[0139] Polymerase chain reactions (PCR) aimed to obtain fragments of the
[0140] ohprKLc1 (5′-GGNRTNGGNAARAGYGARAC-3′)
[0141] ohprKLc2 (5′-RAARTTNCCCCANCGNCC-3′) ii)
[0142] ohprKLc3 (5′-ATAAAGCTTGARMTGACNGGNTAYTTYRAYTWYTA-3′);
[0143] ohprKLc4 (5′-ATTGAAAAGAGCTCGGATTAAGTGCT-3′).
[0144] ohprKLc3 and ohprXLc4 contain restriction sites for HindIII and SacI, respectively, which are indicated in italics.
[0145] Oligonucleotide ohprKLc4 corresponds to the sequence located 9- 35 bp downstream of the hprK stop codon. The C at position 10 of this sequence was replaced with an A and the A in position 12 with a C to allow the creation of the SacI site. To exclude errors introduced by PCR, each DNA fragment was amplified in at least two independent experiments, cloned into pBC KS+(STRATAGENE) (cut with EcoRV or HindIII and SacI) providing plasmids pHKLc1 and pHKLc2, respectively, and sequenced on a PERKIN ELMER ABIPRISM 373 automated sequencer. The fragment of the hprK gene in pHKLc1 was oriented in the same direction as the lacZ fragment.
[0146] By using these two primers and
[0147] To obtain part of the missing sequence of the presumed
[0148] Construction of a
[0149] A point mutation was introduced into the hprK gene of
[0150] A PCR was carried out using plasmid pHKLc2 as a template and the two oligonucleotides:
[0151] ohprKLc5 (5′-CCCCTCGAGGTCGACGGTATGGATAAGCTTGA-3′);
[0152] which contains part of the multiple cloning site of pHKLc2 including a SaIl restriction site (in italics) and a replacement of the C in position 21 by a G (underlined) destroying the ClaI site and :
[0153] ohprKLc6 (5′-CATGACATCGATAATGCCCTAGCCACGAATTTC-3′).
[0154] Oligonucleotide ohprKLc6 is based on the DNA sequence from position 610 to 643 of
[0155] The resulting 522 bp PCR fragment was digested with SaIl and ClaI and cloned into pHKLc1 cut with the same enzymes, thus providing pHKLc3 containing the 3′ part of hprK with the amber mutation and the 5′ part of lgt. Plasmid pHKLc3 was digested with HindIII and SacI and the resulting 1312 bp fragment was cloned into the integrative vector pRV300 cut with the same enzymes to give the 4.8 kb plasmid pHKLc2O8(Am).
[0156] Erythromycin-resistant
[0157] Campbell-like recombination of pHKLc208(Am) with the
[0158] One of the mutants in which the presence of the hprK208(Am) mutation has been confirmed by DNA sequencing of appropriate PCR products was named LcG102 and used for further studies. Chromosomal DNA of LcG102 was isolated, digested with HindIII, religated, transformed into
[0159] The presumed
[0160]
[0161] In order to confirm that the presumed hprK gene encodes indeed
[0162] To purify
[0163] 5′-GTGGGATCCATGGCAGACAGCG-3′ and
[0164] 5′-TACGGTACCAATGAACTTCCA-3′
[0165] containing a BamHI and a KpnI restriction site, respectively (in italics). The resulting 1033 bp fragment containing the complete hprK gene was cut with BamHI and KpnI and cloned into plasmid pQE30 (QIAGEN) cut with the same restriction enzymes to give pQEHKLc. The correct sequence of the amplified hprK was confirmed by DNA sequencing.
[0166] In order to purify His-tagged
[0167] His-tagged
[0168] Using HPr(His)
[0169] The effects of FBP and inorganic phosphate (P
[0170] ATP-dependent HPr phosphorylation was slightly stimulated by FBP at concentrations higher than 1 mM, whereas the P-Ser-HPr phosphatase activity was clearly stimulated by 0.2 mM and higher concentrations of P
[0171] HPr kinase and P-Ser-HPr phosphatase activities were determined in crude extracts of
[0172] Cells were grown in 10 ml MRS medium, harvested by centrifugation and washed twice with 50 mM Tris-HCl buffer, pH 7.4. The pellet was resuspended in 800 μl of the same buffer, cells were broken by sonication (BRANSON SONIFIER 250) and cell debris was removed by centrifugation.
[0173] To demonstrate HPr kinase activity in
[0174] No HPr kinase activity was detected in crude extracts of hprK208(Am) mutant strain.
[0175] To test whether this mutant was also devoid of P-Ser-HPr phosphatase activity, crude extracts of
[0176] P-Ser-HPr phosphatase assays were carried out by incubating a 20 μl assay mixture containing 10 μl crude extract, 2.5 μg
[0177] Whereas P-Ser-HPr phosphates activity could be easily seen with crude extracts of the wild type strain, no activity could be detected with this test in crude extracts of the hprK208(Am) mutant LcG102. Even increasing the incubation time from 10 to 30 min did not allow to detect dephosphorylated HPr in the P-Ser-HPr phosphatase assay with crude extracts of the hprK208(Am) mutant.
[0178] The hprK208(Am) Mutation Affects CCR
[0179] To determine whether similar to
[0180] Wild-type and ccpA, ptsH1 and hprK208(Am) mutant cells were grown in 10 ml MRS fermentation medium to an OD
[0181] In the wild-type strain ATCC 393, N-acetylglucosaminidase activity was repressed 18-fold by the presence of glucose, whereas N-acetylglucoaminidase activity was derepressed in ribose-grown cells (Table 2). Similar as in TABLE 2 N-acetylglucosaminidase activity Strains Glucose Ribose wild-type 2.0 ± 0.9 37.6 ± 6.7 hprk208 (Am) 26.3 ± 1.7 31.5 ± 4.5 ptsHI 26.7 ± 6.5 35.3 ± 7.2 ccpA 19.4 ± 0.7 30.6 ± 4.3
[0182] The hprK208(Am) Mutation Affects Diauxic Growth
[0183] Growth of the hprK208(Am) mutant LcG102 in MRS medium containing 0.05% glucose and either 0.05% lactose or 0.05% maltose was compared to the growth behaviour of the wild-type strain ATCC 393. Wild-type
[0184] The hprK208(Am) Mutation Prevents the Exclusion of Maltose by Alucose
[0185] It is shown above that replacement of Ser-46 in
[0186] Food grade mutants of ptsI or ccpA genes were constructed in the industrial strain of
[0187] Construction of a ptsI Mutant
[0188] This mutant was constructed using the method of Example 2.
[0189] Plasmid pVMR10 was used to transform
[0190] The transformed strain was grown in MRS medium comprising 5 μg/ml erythromycin. An erythromycin-resistant ptsI
[0191] An erythromycin-sensitive Lac clone was isolated as disclosed by Example 2 above, checked by PCR and its ptsI gene sequenced. The fermentation pattern of this clone in API-CH50L showed that, when compared to the wild type CNCM I-1518, this mutant could no longer use adonitol, fructose, mannose, sorbose, mannitol, sorbitol, amygdaline, arbutine, salicine, cellobiose, sucrose and trehalose.
[0192] This mutant was grown at 37° C. in low-fat milk (13 g fat/kg) or skim milk. In skim milk, a pH of 4.45 was reached after 34 h (under the same conditions a pH of 4.45 was reached after 30 h with the wild-type strain CNCM I-1518).
[0193] In another series of tests, standardized milk having 170 g protein/kg, 13 g fat/kg, and supplemented with 50 g glucose/kg was used.
[0194] The fermented products obtained from standardized milk supplemented with glucose with the mutant strain ptsI have a gel-strength lower of about 15-25% than the fermented products obtained from the wild-type strain. This allows to obtain a more elastic gel of about 15-25% and to reduce syneresis.
[0195] They also have a slightly lower viscosity than the fermented products obtained with the wild-type strain. However, the loss of viscosity under shearing is less important in the case of the products obtained with the mutant strain. This property allows a better conservation of the texture during industrial processes wherein shearing may occur, such as the preparation of stirred fermented milk.
[0196] The fermented products obtained with the mutant strain had a more creamy flavour than the fermented products obtained with the wild-type strain. This is related to a higher content in C4, C6, C8, C12, C14, and C16 fatty acids.
[0197] Construction of a ccpA Mutant
[0198] Mutants in
[0199] Plasmid pJDC9 [CHEN and MORRISON, Gene, 64, 155-164, (1998)] carrying a SalI restriction fragment of 2.6 kb that included ccpA gene and flanking regions, was digested with EcoRI, made blunt end (filled in with the Klenow enzyme), ligated and transformed in
[0200] The transformed strains were grown in MRS medium comprising 5 μg/ml erythromycin and erythromycin-resistant integrants were isolated.
[0201] Then, one integrant of each transformation event was grown for 200 generations in MRS medium without erythromycin leading to the excision of the plasmid. Erythromycin-sensitive colonies showing slower growth were screened by PCR amplification of ccpA, followed by digestion with EcoRI. Strains where the amplified fragment was not digested by EcoRI were further analysed by sequencing the ccpA gene. Sequencing of the ccpA mutant gene showed that an insertion of four nucleotides (AATT) had occurred at position 710 of the sequence U28137 of GENBANK. This insertion generated a stop codon 5 codons after the mutation site and resulted in a truncated CcpA protein of 143 amino acids that is inactive.
[0202] When this mutant was grown at 37° C. in skim milk, a pH of 4.45 was reached after 45 h.
[0203] The fermented products obtained with the mutant strain from standardized milk supplemented with glucose had a content in acetic acid, succinic acid, and formic acic twice higher than the fermented products obtained from the wild-type strain. They also contained the same quantity of lactate than the products obtained from the wild-type strain. They contained less citrate, due to a citrate consumption by the ccpA mutant 10 times higher than by the wild-type strain.
[0204] They had also a higher content in acetoin (4 to 6 times higher) than the fermented products obtained from the wild-type strain.
[0205] The overproduction of acetoin by the ccpA mutant indicates that it is potentially able to overproduce diacetyl under appropriate conditions (i.e. oxidative conditions which promotes the conversion of α-acetolactate into diacetyl rather than into acetoin).
[0206] The ptsI and ccpA mutants of Example 5 were grown as described above on standardized milk supplemented with glucose until a pH of about 4.55.
[0207] The fermented milks thus obtained are stored at 4° C., 8° C., or 13° C., and the pH is measured after 7, 14, 21, or 28 days of storage.
[0208]
[0209] Legend of
[0210] ——: wild type strain 4° C.
[0211] —▴—: wild type strain 8° C.
[0212] —♦—: wild type strain 13° C.
[0213] —∘—: ccpA mutant 4° C.
[0214] —Δ—: ccpA mutant 8° C.
[0215] —⋄—: ccpA mutant 13° C.
[0216] ——: ptsI mutant 4° C.
[0217] —▴—: ptsI mutant 8° C.
[0218] —♦—: ptsI mutant 13° C.
[0219] These results show that in every case, the. ccpA and ptsI mutants have a reduced post-acidification compared with the wild-type strain.
[0220] This reduced post-acidification is not due to a lower survival of the mutant strains. This was controlled by measuring the survival rate at 28 days. It is higher than 60% for the ccpA and ptsI mutants as well as for the wild-type strain.